Institutional Biosafety Committee (IBC)
Lewis & Clark’s Institutional Biosafety Policy ensures the protection of faculty, staff, students who generate, process, and dispose of potentially hazardous biological materials at Lewis & Clark, as well as others who may become exposed to biological hazards within the institutional environment. The Institutional Biosafety Committee (IBC) must review and approve all research involving recombinant DNA, synthetic nucleic acid molecules, infectious agents or toxins. The PI must submit an application to the IBC prior to research initiation.
Committee Membership (2019-20)
Nikolaus Loening, Ph.D. - Professor of Chemistry, IBC Chair
Sarah Byers, Ph.D. - Assistant Research Integrity Officer, Oregon Health & Science University
Kelly DelFatti - Assistant VP of SPARC
Janis Lochner, Ph.D - Robert B. Pamplin Jr. Professor of Science
Todd Rosenstiel, Ph.D. - Associate Dean for Research and Graduate Programs for the College of Liberal Arts and Sciences, Portland State University
Administered by the Sponsored Projects and Research Compliance Office. Contact: firstname.lastname@example.org
Institutional Official: Bruce Suttmeier, Ph.D. - Dean of the College of Arts and Sciences
The IBC meets annually, usually in the spring. Minutes of IBC meetings are available upon request. Please contact email@example.com for more information.
Research involving biological materials requires additional training.
The following links will take you away from the L&C website.
- NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) - Frequently Asked Questions
- Experiments that are Exempt from the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) - Frequently Asked Questions